HomeNDC LookupRxCUI directory › RxCUI 1244558

Mitomycin 0.2 MG/ML Ophthalmic Solution [Mitosol] — RxCUI 1244558

RxNorm drug concept · Semantic branded drug
RxCUI 1244558 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1244558
Official nameMitomycin 0.2 MG/ML Ophthalmic Solution [Mitosol]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMitosol 0.2 MG/ML Ophthalmic Solution
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mitomycin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Mitomycin is a chemotherapy drug used for several different conditions depending on the product form. The intravenous versions — Mitomycin for Injection and Mutamycin — are used al...
  • The intravenous form is given through a vein by a trained healthcare professional, usually in a hospital or cancer clinic — you won't take it at home as a pill. It's typically give...
  • How will I receive my mitomycin treatment?
  • The most important thing to watch for is signs of low blood cell counts — things like fever, chills, unusual fatigue, or easy bruising and bleeding. These can be serious and need p...
📖 Read our full Mitomycin guide →

🕸️ Concept Web — How Mitomycin 0.2 MG/ML Ophthalmic Solution [Mitosol... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mitomycin 0.2 MG/ML Ophthalmic Solution [Mitosol] RxCUI 1244558

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mitomycin 632
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Mitosol 1244554
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mitomycin Ophthalmic Solution 1244552
    • Mitomycin Ophthalmic Product 1244551
    • Mitomycin Ophthalmic Solution [Mitosol] 1244556
    • Mitosol Ophthalmic Product 1244557
    • Ophthalmic Solution 7670
    • Ophthalmic Product 1151135
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Mitomycin 0.2 MG/ML [Mitosol] SBDC · 1244555
  • Mitomycin Ophthalmic Solution [Mitosol] SBDF · 1244556
  • Mitosol Ophthalmic Product SBDG · 1244557
  • Mitosol BN · 1244554

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1244558 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
49771-0002-03 3 TRAY in 1 CARTON (49771-002-03) / 1 KIT in 1 TRAY (49771-... Mitosol Mobius Therapeutics LLC 2012-02-08
Observed labelers: Mobius Therapeutics LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.